Anzeige
Mehr »
Login
Freitag, 04.10.2024 Börsentäglich über 12.000 News von 690 internationalen Medien
Citibank´s $3.000-Gold-Prognose und die $60-Millionen-Wette, die den Mining-Sektor neu definieren könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E1GW | ISIN: BE0974464977 | Ticker-Symbol: 2NF
Tradegate
04.10.24
19:48 Uhr
80,90 Euro
+3,06
+3,93 %
1-Jahres-Chart
SYENSQO SA Chart 1 Jahr
5-Tage-Chart
SYENSQO SA 5-Tage-Chart
RealtimeGeldBriefZeit
80,7081,0222:11
80,7081,0022:00
GlobeNewswire (Europe)
744 Leser
Artikel bewerten:
(2)

Syensqo SA: Syensqo announces strategic pension risk management initiative

Syensqo announces strategic pension risk management initiative

Brussels, Belgium - September 17, 2024 - 08:30 CEST

Syensqo announces today a significant step in its ongoing commitment to the financial stability of its retirees in the US and Canada by reducing its pension obligations through the purchase of group annuity contracts. This strategic move is designed to reduce the Company's gross pension obligations and associated volatility risk, while enhancing the long term security of pension benefits for its retirees.

Syensqo has entered in August into agreements with Pacific Life Insurance Company ("Pacific Life") and RBC Insurance ("RBC"), to transfer USD 485 million of its pension obligations with no change to the benefits for its retirees as well as no additional cash funding requirement, as the plans are fully funded.

Christopher Davis, CFO of Syensqo, commented, "This strategic initiative underscores our commitment to the long term financial security of our retirees and of our company. By partnering with top-tier insurance providers, we are ensuring that our pension obligations are managed with the utmost care and expertise, allowing us to focus on delivering value to our stakeholders and advancing our strategy."

"Pacific Life and RBC are proud to work with Syensqo to help provide retirement security for their retirees," said jointly by Karen Neeley, Vice President of the Institutional Retirement Solutions Group at Pacific Life and Abid Kazmi, Vice President Longevity Solutions at RBC. "With the strength, stability, and extensive years of expertise of our companies, we're committed to ensuring the retirement income they worked hard to earn is protected."

RBC will begin paying and administering the retirement benefits of affected retirees and beneficiaries in Canada from December 2024 and Pacific Life will similarly do the same for US retirees and beneficiaries from January 2025.

Safe harbor

This press release may contain forward-looking information. Forward-looking statements describe expectations, plans, strategies, goals, future events or intentions. The achievement of forward-looking statements contained in this press release is subject to risks and uncertainties relating to a number of factors, including general economic factors, interest rate and foreign currency exchange rate fluctuations, changing market conditions, product competition, the nature of product development, impact of acquisitions and divestitures, restructurings, products withdrawals, regulatory approval processes, all-in scenario of R&I projects and other unusual items. Consequently, actual results or future events may differ materially from those expressed or implied by such forward-looking statements. Should known or unknown risks or uncertainties materialize, or should our assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

About Syensqo

Syensqo is a science company developing groundbreaking solutions that enhance the way we live, work, travel and play. Inspired by the scientific councils which Ernest Solvay initiated in 1911, we bring great minds together to push the limits of science and innovation for the benefit of our customers, with a diverse, global team of more than 13,000 associates.
Our solutions contribute to safer, cleaner, and more sustainable products found in homes, food and consumer goods, planes, cars, batteries, smart devices and health care applications. Our innovation power enables us to deliver on the ambition of a circular economy and explore breakthrough technologies that advance humanity.

Investor Relations Resources

  • Earnings materials (https://www.syensqo.com/en/investors/financials/earnings)
  • Strategy (https://www.syensqo.com/en/about-us/our-strategy)
  • Share information (https://www.syensqo.com/en/investors/share-information)
  • Credit information (https://www.syensqo.com/en/investors/financials/bond-information)
  • Separation documents (https://www.syensqo.com/en/investors/spinoff/documents)
  • Webcasts, podcasts and presentations (https://www.syensqo.com/en/investors/financial-calendar-events-and-presentations/webcasts-and-presentations)
  • 2023 Annual Integrated Report (https://www.syensqo.com/en/investors/annual-reports)
  • Subscribe to our distribution list (https://www.syensqo.com/en/investors/investor-relations-contacts)

Contacts

Investors & Analysts Media
Sherief Bakr
+44 7920 575 989

Bisser Alexandrov
+33 607 635 280

investor.relations@syensqo.com (mailto:investor.relations@syensqo.com)
Perrine Marchal
+32 478 32 62 72

Laetitia Schreiber
+32 487 74 38 07

media.relations@syensqo.com (mailto:media.relations@syensqo.com)

Attachment

  • 20240917_Pension buyout agreement_EN (https://ml-eu.globenewswire.com/Resource/Download/bb2232b0-220b-4bab-b457-096b726d48ef)

© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.